Unraveling anxiety and compulsion: Contemporary diagnostic and pharmacogenomic strategies for Advanced Practice Providers
-
Register
- User - $30
Anxiety disorders and compulsive conditions remain among the most prevalent—and often misdiagnosed—mental health challenges encountered in both psychiatric and primary care settings. With the DSM-5-TR emphasizing refined diagnostic boundaries, and the growing availability of pharmacogenomic tools to personalize treatment, nurse practitioners are uniquely positioned to improve outcomes through precision-based, evidence-informed care. This session provides an in-depth exploration of updated diagnostic criteria, emerging disease models, and nuanced differentiation among anxiety-related and compulsive disorders, including generalized anxiety disorder (GAD), panic disorder, social anxiety disorder (SAD), and obsessive-compulsive disorder (OCD).
*Due to rapidly changing clinical knowledge, once purchased, you have 90 days access to complete this education.
Credits: 1.0 Contact Hours; 1.0 are Pharmacology
This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid from 1/1/2026 to 12/31/2026. PAs should only claim credit commensurate with the extent of their participation.
CE Expiration Date: December 31, 2026
$30
LEARNING OBJECTIVES
After taking part in this educational activity, participants should be better able to:
-Develop a working knowledge of updated diagnostic criteria and neurobiological models to improve case identification and differentiation of anxiety and compulsive disorders.
-Apply concepts of pharmacogenomics to the selection, prescription, and management of psychotropic therapy for individuals with anxiety and compulsive disorders.
-Discuss contemporary approaches to the management of anxiety and compulsive disorders, including practical pharmacologic and non-pharmacologic interventions within the scope of nurse practitioner practice.
Josh Hamilton, DNP, RN-BC, FNP-C, PMHNP-BC, CTMH, CNE, FAANP
President & Chief Clinical Officer
The Hamilton Group LLC
Josh Hamilton is a thought leader and edge-runner in mental health nursing. With more than a quarter-century of nursing experience, he maintains a telepsychiatry practice and holds professorial appointments, academic leadership positions and provides extensive professional consultation services in higher education, industry and clinical affairs. He was associate medical director for the largest managed care behavioral health network in the Desert Southwest and, as a university dean and vice president, he built one of the largest portfolio collections of competency-based graduate Nursing degrees in the United States. His professional interests include neurobiology, pharmacology and epigenetics. He is an internationally-recognized speaker on these (and related) topics at conferences and professional meetings. He served on the psychiatric medication working group at the Center of Excellence in Regulatory Science & Innovation, a FDA-sponsored project at the University of Maryland. He is a NEI Master Psychopharmacologist and a fellow of the American Association of Nurse Practitioners. The Point of Care Network proclaimed Josh to be America’s Top Psychiatric NP in 2021. He won the award again in 2024.
feel free to link to my social media at your discretion:
https://www.linkedin.com/in/hamiltondnp/
https://www.linkedin.com/company/the-hamilton-group-behavioral-health
https://www.facebook.com/drjoshhamilton
https://www.facebook.com/hamiltongrouplv
CE/CME INFORMATION
Obtain Your Credits
To earn credits for this activity, navigate to the Content(s) tab and complete all course components in the following order: 1) watch the course presentation video; 2) complete the course evaluation; 3) pass the post-test with a score of 2/3 (66.7%) or higher. You may retake the post-test until a passing score is achieved, at which point you will be able to view/print a copy of your certificate of completion. This online certificate will also be saved within your profile 'My Courses/Certificates' -> 'Transcript/Certificates Earned' for future access.
Designation Statement
NPACE designates this educational activity for a maximum of 1.0 contact hours, of which 1.00 is pharmacology credit. Participants should claim only credit commensurate with the extent of their participation in the activity.
This activity has been reviewed by the American Academy of Physician Associates Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid from 1/1/2026 to 12/31/20266 . PAs should only claim credit commensurate with the extent of their participation.
Accreditation Statement
Nurse Practitioner Associates for Continuing Education is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
DISCLOSURES
Faculty
Contributing faculty, Josh Hamilton, DNP, RN-BC, FNP-C, PMHNP-BC, CNE, FAANPC has disclosed
Tempus Labs, Inc. Consultant, speaker’s bureau Pharmaco-genomic Testing Tempus nP
Point of Care Network Paid Ambassador APP issues N/A
Myriad Neuroscience (ended 2023) Speaker’s bureau Pharmaco-genomic Testing Genesight
Planners
All planners and contributors involved in this educational activity have disclosed no relevant financial relationships.
Disclaimer
The material presented in this continuing education program is being made available for educational purposes only and is not intended to represent the best or only methods, medications and/or guidelines appropriate for the medical situation discussed. Rather the material is intended to present an approach, view, statement, or opinion of the presenter(s), which may be helpful, or of interest to other practitioners and should not be used by clinicians without the evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. NPACE disclaims any liability, loss, injury, or damage incurred as a consequence, directly or indirectly, of the use and application of any information given in a presentation.
Disclosure of Unlabeled Use
This educational activity may mention the uses of products that are not approved by the FDA for the indication(s) being discussed. The presenter(s) are instructed to notify participants when they are discussing unapproved uses or investigational agents. The opinions related to unapproved uses of products are solely those of the presenter(s) and are not endorsed or recommended by NPACE. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Commercial Support
There is no commercial support for this activity.
Key:
Complete
Next
Failed
Available
Locked
